Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,492 | 815 | 549 | 910 | 4,279 |
| Other current assets | 17 | 0 | 203 | 0 | 0 |
| TOTAL | $2,145 | $1,601 | $1,591 | $2,062 | $6,071 |
| Non-Current Assets | |||||
| PPE Net | 4 | 4 | 5 | 4 | 3 |
| Other Non-Current Assets | 320 | 55 | 105 | 263 | 377 |
| TOTAL | $324 | $60 | $110 | $266 | $381 |
| Total Assets | $2,469 | $1,661 | $1,701 | $2,328 | $6,452 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 6,640 | 5,878 | 5,832 | 4,027 | 3,571 |
| Accrued Expenses | N/A | N/A | N/A | N/A | 260 |
| TOTAL | $6,763 | $6,091 | $6,133 | $4,069 | $3,997 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $6,763 | $6,091 | $6,133 | $4,069 | $3,997 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 54 | 0 | 0 | 0 | 0 |
| Common Shares | 1 | 11 | 0 | 4 | 4 |
| Retained earnings | -75,642 | -73,112 | -69,567 | -64,192 | -59,669 |
| TOTAL | $-4,294 | $-4,431 | $-4,432 | $-1,741 | $2,454 |
| Total Liabilities And Equity | $2,469 | $1,661 | $1,701 | $2,328 | $6,452 |